CTOs on the Move

Medizone International

www.medizoneint.com

 
Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets, through its expanding distributor network. The ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medizoneint.com
  • 350 East Michigan Avenue Suite 500
    Kalamazoo, MI USA 49007
  • Phone: 269.202.5020

Executives

Name Title Contact Details

Similar Companies

Confluent Medical Technologies

Confluent Medical Technologies is the leading contract manufacturer of Nitinol-based components, balloon components, and balloon catheters.

Groupe Essaim

Groupe Essaim Inc. is a Boucherville, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Circassia

Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies.

Validation Inc

Validation Inc is a Whitehall, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurogastrx

We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.